目的:探讨稳定期精神分裂症患者的孤独感与被动自杀意念的相关性。方法:采用孤独感自评量表(UCLA Loneliness Scale,UCLA)、简明国际神经精神访谈中文版自杀分量表(The suicide subscale of the Chinese version of Mini-International ...目的:探讨稳定期精神分裂症患者的孤独感与被动自杀意念的相关性。方法:采用孤独感自评量表(UCLA Loneliness Scale,UCLA)、简明国际神经精神访谈中文版自杀分量表(The suicide subscale of the Chinese version of Mini-International Neuropsychiatric Interview,MINI)和自制的一般情况调查量表,对在某心理卫生医院确诊为精神分裂症的208例患者进行调查分析。结果:208名稳定期精神分裂症患者中175例被动自杀意念呈阳性(84.13%);单因素分析发病情况(t=-2.434,P<0.05)、病程(F=18.821,P<0.001)、累计住院年数(F=13.776,P<0.001)是稳定期精神分裂症患者被动自杀意念的影响因素;相关系数分析结果显示年龄与被动自杀意念呈现正相关(r=0.322,P<0.001)、孤独感与被动自杀意念呈现正相关(r=0.565,P<0.001);多元回归分析结果显示累计住院年数(β=1.620,P<0.05)和孤独感(β=0.408,P<0.001)是稳定期精神分裂症被动自杀意念的独立影响因素,差异具有统计学意义。结论:孤独感和累计住院年数是稳定期精神分裂症患者产生被动自杀意念的独立影响因素;稳定期精神分裂症患者孤独感越高,其被动自杀意念越强。展开更多
Objective This study aimed to evaluate whether the onset of the plateau phase of slow hepatitis B surface antigen decline in patients with chronic hepatitis B treated with intermittent interferon therapy is related to...Objective This study aimed to evaluate whether the onset of the plateau phase of slow hepatitis B surface antigen decline in patients with chronic hepatitis B treated with intermittent interferon therapy is related to the frequency of dendritic cell subsets and expression of the costimulatory molecules CD40,CD80,CD83,and CD86.Method This was a cross-sectional study in which patients were divided into a natural history group(namely NH group),a long-term oral nucleoside analogs treatment group(namely NA group),and a plateau-arriving group(namely P group).The percentage of plasmacytoid dendritic cell and myeloid dendritic cell subsets in peripheral blood lymphocytes and monocytes and the mean fluorescence intensity of their surface costimulatory molecules were detected using a flow cytometer.Results In total,143 patients were enrolled(NH group,n=49;NA group,n=47;P group,n=47).The results demonstrated that CD141/CD1c double negative myeloid dendritic cell(DNmDC)/lymphocytes and monocytes(%)in P group(0.041[0.024,0.069])was significantly lower than that in NH group(0.270[0.135,0.407])and NA group(0.273[0.150,0.443]),and CD86 mean fluorescence intensity of DNmDCs in P group(1832.0[1484.0,2793.0])was significantly lower than that in NH group(4316.0[2958.0,5169.0])and NA group(3299.0[2534.0,4371.0]),Adjusted P all<0.001.Conclusion Reduced DNmDCs and impaired maturation may be associated with the onset of the plateau phase during intermittent interferon therapy in patients with chronic hepatitis B.展开更多
目的评价桑丹通络颗粒治疗阴虚血瘀证缺血性脑卒中恢复期的临床有效性与安全性。方法采用回顾性队列研究方法,通过湖南省中医药研究院附属医院门诊与住院病历系统收集2021年7月至2022年6月收治的缺血性脑卒中恢复期患者临床资料,选择应...目的评价桑丹通络颗粒治疗阴虚血瘀证缺血性脑卒中恢复期的临床有效性与安全性。方法采用回顾性队列研究方法,通过湖南省中医药研究院附属医院门诊与住院病历系统收集2021年7月至2022年6月收治的缺血性脑卒中恢复期患者临床资料,选择应用桑丹通络颗粒联合西医常规治疗的51例患者为暴露组,匹配仅应用西医常规治疗的102例患者为对照组,两组均治疗2周。比较治疗前后总有效率、美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、日常生活活动能力(activity of daily living,ADL)评分、血脂水平、血液流变学指标和症状总积分等,并对所有患者治疗期间不良反应事件进行记录。结果暴露组临床总有效率84.31%,高于对照组的67.65%(P<0.05)。与治疗前比较,两组治疗后NIHSS、TC、LDL降低(P<0.01或P<0.05),且暴露组低于对照组(P<0.05);两组ADL升高(P<0.01),且暴露组高于对照组(P<0.01)。与治疗前比较,暴露组治疗后症状总积分、血液流变学各项指标降低(P<0.01或P<0.05),且暴露组低于对照组(P<0.01或P<0.05);HDL-C升高(P<0.01),且暴露组高于对照组(P<0.01)。结论桑丹通络颗粒联合西医常规治疗可明显改善阴虚血瘀证缺血性脑卒中恢复期患者症状,降低其神经缺损程度,改善血脂水平和血液流变学指标,有效提高其生存质量,疗效确切且安全稳定。因此,推测桑丹通络颗粒具有一定的临床应用与推广价值。展开更多
文摘目的:探讨稳定期精神分裂症患者的孤独感与被动自杀意念的相关性。方法:采用孤独感自评量表(UCLA Loneliness Scale,UCLA)、简明国际神经精神访谈中文版自杀分量表(The suicide subscale of the Chinese version of Mini-International Neuropsychiatric Interview,MINI)和自制的一般情况调查量表,对在某心理卫生医院确诊为精神分裂症的208例患者进行调查分析。结果:208名稳定期精神分裂症患者中175例被动自杀意念呈阳性(84.13%);单因素分析发病情况(t=-2.434,P<0.05)、病程(F=18.821,P<0.001)、累计住院年数(F=13.776,P<0.001)是稳定期精神分裂症患者被动自杀意念的影响因素;相关系数分析结果显示年龄与被动自杀意念呈现正相关(r=0.322,P<0.001)、孤独感与被动自杀意念呈现正相关(r=0.565,P<0.001);多元回归分析结果显示累计住院年数(β=1.620,P<0.05)和孤独感(β=0.408,P<0.001)是稳定期精神分裂症被动自杀意念的独立影响因素,差异具有统计学意义。结论:孤独感和累计住院年数是稳定期精神分裂症患者产生被动自杀意念的独立影响因素;稳定期精神分裂症患者孤独感越高,其被动自杀意念越强。
基金supported by the National Key Research and Development Program[2022YFC2603500,2022YFC2603505]Capital Clinical Diagnostic Techniques and Translational Application Projects(Z211100002921059)+2 种基金Capital’s Funds for Health Improvement and Research[2022-1-2172]Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support[XMLX 202127]National Science and Technology Major Project of China[2017ZX10203202-003]。
文摘Objective This study aimed to evaluate whether the onset of the plateau phase of slow hepatitis B surface antigen decline in patients with chronic hepatitis B treated with intermittent interferon therapy is related to the frequency of dendritic cell subsets and expression of the costimulatory molecules CD40,CD80,CD83,and CD86.Method This was a cross-sectional study in which patients were divided into a natural history group(namely NH group),a long-term oral nucleoside analogs treatment group(namely NA group),and a plateau-arriving group(namely P group).The percentage of plasmacytoid dendritic cell and myeloid dendritic cell subsets in peripheral blood lymphocytes and monocytes and the mean fluorescence intensity of their surface costimulatory molecules were detected using a flow cytometer.Results In total,143 patients were enrolled(NH group,n=49;NA group,n=47;P group,n=47).The results demonstrated that CD141/CD1c double negative myeloid dendritic cell(DNmDC)/lymphocytes and monocytes(%)in P group(0.041[0.024,0.069])was significantly lower than that in NH group(0.270[0.135,0.407])and NA group(0.273[0.150,0.443]),and CD86 mean fluorescence intensity of DNmDCs in P group(1832.0[1484.0,2793.0])was significantly lower than that in NH group(4316.0[2958.0,5169.0])and NA group(3299.0[2534.0,4371.0]),Adjusted P all<0.001.Conclusion Reduced DNmDCs and impaired maturation may be associated with the onset of the plateau phase during intermittent interferon therapy in patients with chronic hepatitis B.
文摘目的评价桑丹通络颗粒治疗阴虚血瘀证缺血性脑卒中恢复期的临床有效性与安全性。方法采用回顾性队列研究方法,通过湖南省中医药研究院附属医院门诊与住院病历系统收集2021年7月至2022年6月收治的缺血性脑卒中恢复期患者临床资料,选择应用桑丹通络颗粒联合西医常规治疗的51例患者为暴露组,匹配仅应用西医常规治疗的102例患者为对照组,两组均治疗2周。比较治疗前后总有效率、美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、日常生活活动能力(activity of daily living,ADL)评分、血脂水平、血液流变学指标和症状总积分等,并对所有患者治疗期间不良反应事件进行记录。结果暴露组临床总有效率84.31%,高于对照组的67.65%(P<0.05)。与治疗前比较,两组治疗后NIHSS、TC、LDL降低(P<0.01或P<0.05),且暴露组低于对照组(P<0.05);两组ADL升高(P<0.01),且暴露组高于对照组(P<0.01)。与治疗前比较,暴露组治疗后症状总积分、血液流变学各项指标降低(P<0.01或P<0.05),且暴露组低于对照组(P<0.01或P<0.05);HDL-C升高(P<0.01),且暴露组高于对照组(P<0.01)。结论桑丹通络颗粒联合西医常规治疗可明显改善阴虚血瘀证缺血性脑卒中恢复期患者症状,降低其神经缺损程度,改善血脂水平和血液流变学指标,有效提高其生存质量,疗效确切且安全稳定。因此,推测桑丹通络颗粒具有一定的临床应用与推广价值。
